American Shared Hospital Services — Q1 2024 Form 10-Q
Business context and period. The company provides Gamma Knife radiosurgery and proton beam radiation therapy (PBRT) equipment and services through equipment leasing and direct-treatment facilities. This summary covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. The Rhode Island acquisition closed after quarter-end, on May 7, 2024.
Key financial results
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $5.216 million | $4.925 million; up 5.9% |
| Gross margin | $2.143 million; 41.1% of revenue | $1.908 million; 38.7% |
| Operating loss (as presented) | $85,000 | Operating income of $98,000 |
| Net income | $65,000 | $100,000 |
| Net income attributable to ASHS | $119,000; $0.02 per diluted share | $188,000; $0.03 per diluted share |
| Cash from operating activities | Used $1.865 million | Provided $1.761 million |
| Cash, cash equivalents and restricted cash | $13.042 million at March 31 | $13.808 million at December 31, 2023 |
| Long-term debt, net of issuance costs | $15.602 million | Balance sheet total liabilities were $23.739 million |
- Leasing revenue was $4.253 million, up $24,000; retail revenue was $963,000, up $267,000. PBRT revenue rose $335,000 to $2.649 million, while Gamma Knife revenue declined $44,000 to $2.567 million.
- PBRT fractions fell to 1,276 from 1,536. Gamma Knife procedures declined to 273 from 293, primarily reflecting two customer contracts that expired in 2023; excluding those contracts, procedures increased 4%.
- Selling and administrative expense rose $340,000 to $1.879 million, including approximately $377,000 in fees associated with new business opportunities. Interest expense rose $78,000 to $349,000 amid higher SOFR and borrowings.
- Working capital was $10.586 million, up $909,000 from year-end. Current assets were $21.365 million and current liabilities $10.779 million. The company had $2.4 million drawn on its $7 million revolving line at quarter-end; that amount was repaid in April.
Material changes, outlook and risks
- Operating cash flow turned negative, chiefly due to a $2.138 million increase in receivables and a $1.898 million reduction in related-party liabilities. Investing cash outflow was $1.183 million, including equipment purchases. Financing provided $2.282 million, including a $2.7 million supplemental term loan.
- The company reports $13.752 million of equipment purchase and installation commitments and $14.120 million of service commitments. It intends to finance substantially all equipment commitments, but says financing may not be available on acceptable terms. It cites cash on hand and its credit line as funding resources.
- Management expects cash on hand, operating cash flow and other resources to cover working capital and scheduled debt obligations over the next 12 months; scheduled principal and interest payments are approximately $3.997 million. No specific earnings or revenue guidance is provided.
- The Fifth Third facilities carry a floating rate of SOFR plus 3%. The company reported compliance with its covenants at March 31. DFC waived and amended certain covenants through December 31, 2024; the company reported compliance under the amended terms.
- On May 7, 2024, ASHS completed its purchase of a 60% interest in two Rhode Island radiation therapy companies for $2.85 million. It paid a further $175,000 for equipment on May 14. Purchase accounting was incomplete when the filing was prepared. The company added risks concerning integration, diligence, assumed obligations and potential liabilities of the acquired businesses.
- Q1 income tax benefit was $44,000 and included a non-recurring $100,000 adjustment for unrecognized foreign tax benefits. Other cited risks include reimbursement changes, customer and procedure volumes, equipment obsolescence, debt and financing availability, and acquisition integration.
Important facts for investors to verify
- Whether operating cash flow improves and receivables are collected, given the Q1 cash outflow and receivables increase.
- Availability and terms of financing for the sizable equipment and service commitments, alongside debt maturities and floating-rate exposure.
- Post-acquisition financial performance, integration costs, assumed payor contracts and liabilities, and the completed purchase-price allocation for the Rhode Island businesses.
- Whether PBRT reimbursement and retail growth can offset lower Gamma Knife volumes and the loss of two customer contracts.
- The sustainability of reported earnings, including the effect of acquisition-related expenses and the non-recurring tax adjustment.